Antimicrobial peptides for Gram-negative sepsis: A case for the polymyxins

Frontiers in Immunology

Volumn 3, Issue AUG, 2012, Pages

  David, Sunil A ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84874216415     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2012.00252     Document Type: Article

References (88)

1. Andersson, U., and Tracey, K. J. (2011). HMGB1 is a thera-peutic target for sterile inflammation and infection. Annu. Rev. Immunol. 29, 139-162.
2. Balk, R. A., and Bone, R. C. (1989). The septic syndrome. Definition and clinical implications. Crit. Care Clin. 5, 1-8.
3. Bergen, P. J., Li, J., Rayner, C. R., and Nation, R. L. (2006). Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50, 1953-1958.
4. Beutler, B., and Poltorak, A. (2001). The sole gateway to endotoxin response: how LPS was identified as TLR4, and its role in innate immunity. Drug Metab. Dispos. 29, 474-478.
5. Bone, R. C. (1993). Gram-negative sepsis: a dilemma of modern medicine. Clin. Microbiol. Rev. 6, 57-68.
6. Bone, R. C., Balk, R. A., Fein, A. M., Perl, T. M., Wenzel, R. P., Reines, H. D., Quenzer, R. W., Iberti, T. J., Macintyre, N., and Schein, R. M. (1995). A second large con-trolled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 sepsis study group. Crit. Care Med. 23, 994-1006. [see comments]
7. Bone, R. C., Sprung, C. L., and Sibbald, W. J. (1992). Definitions for sepsis and organ failure. Crit. Care Med. 20, 724-726.
8. Castellheim, A., Brekke, O. L., Espevik, T., Harboe, M., and Mollnes, T. E. (2009). Innate immune responses to danger signals in systemic inflammatory response syndrome and sepsis. Scand. J. Immunol. 69, 479-491.
9. Chedid, L., Parant, M., and Parant, F. (1968). A proposed mechanism for natural immunity to enterobacterial pathogens. J. Immunol. 100, 292-306.
10. Cho, Y. S., Yim, H., Yang, H. T., Hur, J., Chun, W., Kim, J. H., Lee, B. C., Seo, D. K., Park, J. M., and Kim, D. (2012). Use of parenteral colistin for the treatment of multiresistant Gram-negative organisms in major burn patients in South Korea. Infection 40, 27-33.
11. Christ, W. J., Asano, O., Robidoux, A. L. C., Perez, M., Wang, Y., Dubuc, G. R., Gavin, W. E., Hawkins, L. D., McGuinness, P. D., Mullarkey, M. A., Lewis, M. D., Kishi, Y., Kawata, T., Bristol, J. R., Rose, J. R., Rossignol, D. P., Kobayashi, S., Hishinuma, I., Kimura, A., Asakawa, N., Katayama, K., and Yamatsu, I. (1995). E5531, a pure endotoxin antagonist of high potency. Science 268, 80-83.
12. Couet, W., Gregoire, N., Marchand, S., and Mimoz, O. (2012). Colistin pharmacokinetics: the fog is lifting. Clin. Microbiol. Infect. 18, 30-39.
13. Cross, A., and Opal, S. M. (1994). Therapeutic interven-tion in sepsis with antibody to endotoxin: is there a future? J. Endotoxin Res. 1, 57-59.
14. Cruz, D. N., Antonelli, M., Fumagalli, R., Foltran, F., Brienza, N., Donati, A., Malcangi, V., Petrini, F., Volta, G., Bobbio Pallavicini, F. M., Rottoli, F., Giunta, F., and Ronco, C. (2009). Early use of polymyxin B hemop-erfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 301, 2445-2452.
15. Di Padova, F., Brade, H., Barclay, G. R., Poxton, I. R., Liehl, E., Schuetze, E., Kocher, H. P., Ramsay, G., Schreier, M. H., McClelland, D. B. L., and Rietschel, E. T. (1993). A broadly cross-protective monoclonal antibody bind-ing to Escherichia coli and Salmonella lipopolysac-charide. Infect. Immun. 61, 3863-3872.
16. Dinarello, C. A. (1991). The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treat-ment of the septic shock syndrome. J. Infect. Dis. 163, 1177-1184.
17. Dinarello, C. A. (1996). Cytokines as mediators in the pathogenesis of septic shock. Curr. Top. Microbiol. Immunol. 216, 133-165.
18. Durakovic, N., Radojcic, V., Boban, A., Mrsic, M., Sertic, D., Serventi-Seiwerth, R., Nemet, D., and Labar, B. (2011). Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis. Intern. Med. 50, 1009-1013.
19. Durando, M. M., MacKay, R. J., Linda, S., and Skelley, L. A. (1994). Effects of polymyxin B and Salmonella typhimurium antiserum on horses given endotoxin intravenously. Am. J. Vet. Res. 55, 921-927.
20. Ehrentraut, S., Lohner, R., Schwederski, M., Ehrentraut, H., Boehm, O., Noga, S., Langhoff, P., Baumgarten, G., Meyer, R., and Knuefermann, P. (2011). In vivo toll- like receptor 4 antagonism restores cardiac function during endotoxemia. Shock 36, 613-620.
21. Falagas, M. E., and Kasiakou, S. K. (2006). Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit. Care 10, R27.
22. Felty, A. R., and Keefer, C. S. (1924). Bacillus coli sepsis: a clinical study of twenty-eight cases of bloodstream infection by the colon bacillus. JAMA 82, 1430-1433.
23. Fitzpatrick, M. A., Esterly, J. S., Postelnick, M. J., and Sutton, S. H. (2012). Successful treatment of extensively drug- resistant Acinetobacter baumannii peritoneal dialysis peritonitis with intraperitoneal polymyxin B and ampicillin-sulbactam. Ann. Pharmacother. 46, e17.
24. Gales, A. C., Jones, R. N., and Sader, H. S. (2011). Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY antimicro-bial surveillance program (2006-09). J. Antimicrob. Chemother. 66, 2070-2074.
25. Gelfand, J. A., and Shapiro, L. (1993). Cytokines and sep-sis: pathophysiology and therapy. New Horiz. 1, 13-22.
26. Giamarellou, H., and Poulakou, G. (2009). Multidrug- resistant Gram-negative infections: what are the treat-ment options? Drugs 69, 1879-1901.
27. Hennessy, E. J., Parker, A. E., and O'Neill, L. A. (2010). Targeting toll-like receptors: emerging therapeutics? Nat. Rev. Drug Discov. 9, 293-307.
28. Holzheimer, R. G. (2001). Antibiotic induced endotoxin release and clinical sepsis: a review. J. Chemother. 13, 159-172.
29. Hotchkiss, R. S., Coopersmith, C. M., McDunn, J. E., and Ferguson, T. A. (2009). The sepsis seesaw: tilting toward immunosuppression. Nat. Med. 15, 496-497.
30. Hotchkiss, R. S., and Karl, I. E. (2003). The pathophysi-ology and treatment of sepsis. N. Engl. J. Med. 348, 138-150.
31. Iwagaki, A., Porro, M., and Pollack, M. (2000). Influence of synthetic antiendotoxin peptides on lipopolysac-charide (LPS) recognition and LPS-induced proin-flammatory cytokine responses by cells expressing membrane-bound CD14. Infect. Immun. 68, 1655-1663.
32. Jerala, R., and Porro, M. (2004). Endotoxin neutralizing peptides. Curr. Top. Med. Chem. 4, 1173-1184.
33. Jones, W. II, Minei, J., Barber, A., Fahey, T., and Shires, G. T. III. (1991). Splanchnic vasoconstriction and bacte-rial translocation after thermal injury. Am. J. Physiol. 261, H1190-H1196.
34. Jounai, N., Kobiyama, K., and Takeshita, F. (2012). Intracellular inflammatory sensors for foreign invad-ers and substances of self-origin. Adv. Exp. Med. Biol. 738, 60-78.
35. Kawata, T., Bristol, J. R., Rossignol, D. P., Rose, J. R., Kobayashi, S., Yokohama, H., Ishibashi, A., Christ, W. J., Katayama, K., Yamatsu, I., and Kishi, Y. (1999). E5531, a synthetic non-toxic lipid A derivative blocks the immunobiological activities of lipopolysaccha-ride. Br. J. Pharmacol. 127, 853-862.
36. Kim, K. S., Kang, J. H., Cross, A. S., Kaufman, B., Zollinger, W., and Sadoff, J. (1988). Functional activities of mon-oclonal antibodies to the O side chain of Escherichia coli lipopolysaccharides in vitro and in vivo. J. Infect. Dis. 157, 47-53.
37. Kwa, A., Kasiakou, S. K., Tam, V. H., and Falagas, M. E. (2007). Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert. Rev. Anti. Infect. Ther. 5, 811-821.
38. Le Roy, D., Di Padova, F., Tees, R., Lengacher, S., Landmann, R., Glauser, M. P., Calandra, T., and Heumann, D. (1999). Monoclonal antibodies to murine lipopolysaccharide (LPS)-binding protein (LBP) protect mice from lethal endotoxemia by block-ing either the binding of LPS to LBP or the presen-tation of LPS/LBP complexes to CD14. J. Immunol. 162, 7454-7460.
39. Lim, L. M., Ly, N., Anderson, D., Yang, J. C., MacAnder, L., Jarkowski, A. III, Forrest, A., Bulitta, J. B., and Tsuji, B. T. (2010). Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 30, 1279-1291.
40. Martin, G. S., Mannino, D. M., Eaton, S., and Moss, M. (2003). The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348, 1546-1554.
41. Michalopoulos, A., and Falagas, M. E. (2008). Colistin and polymyxin B in critical care. Crit. Care Clin. 24, 377-391.
42. Mizuyachi, K., Hara, K., Wakamatsu, A., Nohda, S., and Hirama, T. (2011). Safety and pharmacokinetic evaluation of intravenous colistin methanesulfonate sodium in Japanese healthy male subjects. Curr. Med. Res. Opin. 27, 2261-2270.
43. Morrison, D. C., and Jacobs, D. M. (1976). Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. Immunochemistry 13, 813-818.
44. Moss, M., and Martin, G. S. (2004). A global perspective on the epidemiology of sepsis. Intensive Care Med. 30, 527-529.
45. Nakamura, T., Ebihara, I., Shoji, H., Ushiyama, C., Suzuki, S., and Koide, H. (1999). Treatment with polymyxin B-immobilized fiber reduces platelet activation in sep-tic shock patients: decrease in plasma levels of soluble P-selectin, platelet factor 4 and beta-thromboglobulin. Inflamm. Res. 48, 171-175.
46. Nakamura, T., Ushiyama, C., Suzuki, Y., Inoue, T., Shoji, H., Shimada, N., and Koide, H. (2003). Combination therapy with polymyxin B-immobilized fibre hae-moperfusion and teicoplanin for sepsis due to methicillin-resistant Staphylococcus aureus. J. Hosp. Infect. 53, 58-63.
47. Nakamura, T., Ushiyama, C., Suzuki, Y., Shoji, H., Shimada, N., and Koide, H. (2002). Hemoperfusion endo-with polymyxin B immobilized fibers for urinary albumin excretion in septic patients with trauma. ASAIO J. 48, 244-248.
48. Nation, R. L., and Li, J. (2009). Colistin in the 21st century. Curr. Opin. Infect. Dis. 22, 535-543.
49. Newton, K., and Dixit, V. M. (2012). Signaling in innate immunity and inflammation. Cold Spring Harb. Perspect. Biol. 4, a006049.
50. Nikaido, H., and Vaara, M. (1985). Molecular basis of bacterial outer membrane permeability. Microbiol. Rev. 49, 1-32.
51. Olive, C. (2012). Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adju-vants. Expert. Rev. Vaccines. 11, 237-256.
52. Oliveira, M. S., Prado, G. V., Costa, S. F., Grinbaum, R. S., and Levin, A. S. (2009). Polymyxin B and colistimeth-ate are comparable as to efficacy and renal toxicity. Diagn. Microbiol. Infect. Dis. 65, 431-434.
53. Palsson-McDermott, E. M., and O'Neill, L. A. (2004). Signal transduction by the lipopolysaccharide recep-tor, toll-like receptor-4. Immunology 113, 153-162.
54. Peterson, A., Hancock, R. E. W., and McGroarty, E. J. (1985). Binding of polycationic antibiotics and polyamines to lipopolysaccharides of Pseudomonas aeruginosa. J. Bacteriol. 164, 1256-1261.
55. Porro, M. (1994). Structural basis of endotoxin recog-nition by natural polypeptides. Trends. Microbiol. 2, 65-66.
56. Porro, M., Rustici, A., Velucchi, M., Agnello, D., Villa, P., and Ghezzi, P. (1998). Natural and synthetic poly-peptides that recognize the conserved lipid a binding site of lipopolysaccharides. Prog. Clin. Biol. Res. 397, 315-325.
57. Ramasubban, S., Majumdar, A., and Das, P. S. (2008). Safety and efficacy of polymyxin B in multidrug resistant Gram-negative severe sepsis and septic shock. Indian J. Crit. Care Med. 12, 153-157.
58. Ranieri, V. M., Thompson, B. T., Barie, P. S., Dhainaut, J. F., Douglas, I. S., Finfer, S., Gardlund, B., Marshall, J. C., Rhodes, A., Artigas, A., Payen, D., Tenhunen, J., Al Khalidi, H. R., Thompson, V., Janes, J., Macias, W. L., Vangerow, B., and Williams, M. D. (2012). Drotrecogin alfa (activated) in adults with septic shock. N. Engl. J. Med. 366, 2055-2064.
59. Rietschel, E. T., Brade, H., Brade, L., Brandenburg, K., Schade, U. F., Seydel, U., Z"hringer, U., Galanos, C., Lüderitz, O., Westphal, O., Labischinski, H., Kusumoto, S., and Shiba, T. (1987). Lipid A, the endo-toxic center of bacterial lipopolysaccharides: Relation of chemical structure to biological activity. Prog. Clin. Biol. Res. 231, 25-53.
60. Rietschel, E. T., Kirikae, T., Schade, F. U., Mamat, U., Schmidt, G., Loppnow, H., Ulmer, A. J., Zähringer, U., Seydel, U., Di Padova, F., Schreier, M., and Brade, H. (1994). Bacterial endotoxin: molecular relation-ships of structure to activity and function. FASEB J. 8, 217-225.
61. Rimmele, T., and Kellum, J. A. (2011). Clinical review: blood purification for sepsis. Crit. Care 15, 205.
62. Rocke, D., Gaffin, S., Wells, M., Koen, Y., and Brocke- Utine, J. (1987). Endotoxemia associated with car-diopulmonary bypass. J. Thorac. Cardiovasc. Surg. 93, 832-837.
63. Rocque, W. J., Fesik, S. W., Haug, A., and McGroarty, E. J. (1988). Polycation binding to isolated lipopolysaccha-ride from antibiotic-hypersusceptible mutant strains of Escherichia coli. Antimicrob. Agents Chemother. 32, 308-313.
64. Rose, J. R., Mullarkey, M. A., Christ, W. J., Hawkins, L. D., Lynn, M., Kishi, Y., Wasan, K. M., Peteherych, K., and Rossignol, D. P. (2000). Consequences of interaction of a lipophilic endotoxin antagonist with plasma lipoproteins. Antimicrob. Agents Chemother. 44, 504-510.
65. Rustici, A., Velucchi, M., Faggioni, R., Sironi, M., Ghezzi, P., Quataert, S., Green, B., and Porro, M. (1993). Molecular mapping and detoxification of the lipid A binding site by synthetic peptides. Science 259, 361-365.
66. Saadia, R., Schein, M., MacFarlane, C., and Boffard, K. (1990). Gut barrier function and the surgeon. Br. J. Surg. 77, 487-492.
67. Scott, M. G., Vreugdenhil, A. C., Buurman, W. A., Hancock, R. E., and Gold, M. R. (2000). Cationic antimicrobial peptides block the binding of lipopoly-saccharide (LPS) to LPS binding protein. J. Immunol. 164, 549-553.
68. Siegel, J. P. (1995). Antiendotoxin antibodies. Ann. Intern. Med. 122, 315-316.
69. Spapen, H., Jacobs, R., Van, G. V., Troubleyn, J., and Honore, P. M. (2011). Renal and neurological side effects of colistin in critically ill patients. Ann. Intensive. Care 1, 14.
70. Stokes, D. C., Shenep, J. L., Fishman, M. L., Hidner, W. K., Bysani, G. K., and Rufus, K. (1989). Polymyxin B prevents lipopolysaccharide-induced release of tumor necrosis factor-α from alveolar macrophages. J. Infect. Dis. 160, 52-57.
71. Storm, D. R., and Rosenthal, K. (1977). Polymyxin and related peptide antibiotics. Annu. Rev. Biochem. 46, 723-763.
72. Thomas, L. (1975). The Lives of a Cell. New York: Penguin Books.
73. Tidswell, M., and Larosa, S. P. (2011). Toll-like recep-tor-4 antagonist eritoran tetrasodium for severe sepsis. Expert. Rev. Anti. Infect. Ther. 9, 507-520.
74. Vaara, M. (1983). Polymyxin B nonapeptide complexes with lipopolysaccharide. FEMS Microbiol. Lett. 18, 117-121.
75. Vaara, M., and Vaara, T. (1983). Polycations as outer membrane disorganizing agents. Antimicrob. Agents Chemother. 24, 114-122.
76. Vaarala, O., Vaara, M., and Palosuo, T. (1988). Effective inhibition of cardiolipin-binding antibodies in gram- negative infections by bacterial lipopolysaccharide. Scand. J. Immunol. 28, 607-612.
77. Viljanen, P., Matsunaga, H., Kimura, Y., and Vaara, M. (1991). The outer membrane permeability-increasing action of deacylpolymyxins. J. Antibiot. 44, 517-523.
78. Wang, H., Bloom, O., Zhang, M., Vishnubhakat, J. M., Ombrellino, M., Che, J., Frazier, A., Yang, H., Ivanova, S., Borovikova, L., Manogue, K. R., Faist, E., Abraham, E., Andersson, J., Andersson, U., Molina, P. E., Abumrad, N. N., Sama, A., and Tracey, K. J. (1999). HMG-1 as a late mediator of endotoxin lethality in mice. Science 285, 248-251.
79. Wenzel, R. P., and Edmond, M. B. (2012). Septic shock - evaluating another failed treatment. N. Engl. J. Med. 366, 2122-2124.
80. Williams, S. C. (2012). After Xigris, researchers look to new targets to combat sepsis. Nat. Med. 18, 1001.
81. Wittebole, X., Castanares-Zapatero, D., and Laterre, P. F. (2010). Toll-like receptor 4 modulation as a strategy to treat sepsis. Mediators Inflamm. 2010, 1-9.
82. Yao, Y. M., Tian, H. M., Sheng, Z. Y., Wang, Y. P., Yu, Y., Sun, S. R., and Xu, S. H. (1995). Inhibitory effects of low-dose polymyxin B on hemorrhage-induced endo- toxin/bacterial translocation and cytokine formation in rats. J. Trauma 38, 924-930.
83. Zavascki, A. P., Goldani, L. Z., Li, J., and Nation, R. L. (2007). Polymyxin B for the treatment of multidrug- resistant pathogens: a critical review. J. Antimicrob. Chemother. 60, 1206-1215.
84. Zeni, F., Freeman, B., and Natanson, C. (1997). Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit. Care Med. 25, 1097-1100.
85. Ziegler, E. J. (1988). Protective antibody to endotoxin core: the emperor's new clothes? J. Infect. Dis. 158, 286-290.
86. Ziegler, E. J., Fisher, C. J. Jr., Sprung, C. L., Straube, R. C., Sadoff, J. C., Foulke, G. E., Wortel, C. H., Fink, M. P., Dellinger, R. P., Teng, N. N. H., Allen, I. E., Berger, H. J., Knatterud, G. L., LoBuglio, A. F., Smith, C. R., and Study Group, A. S. (1991). Treatment of gram- negative bacteremia and septic shock with HA- 1A human monoclonal antibody against endotoxin - aA randomized, double-blind, placebo-controlled trial. N. Engl. J. Med. 324, 429-436.
87. Ziegler, E. J., McCutchan, J. A., Fierer, J., Glauser, M. P., Sadoff, J. C., Douglas, H., and Braude, A. I. (1982). Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N. Engl. J. Med. 307, 1225-1230.
88. Ziegler, E. J., and Smith, C. R. (1992). Anti-endotoxin monoclonal antibodies. N. Engl. J. Med. 326, 1165.